According to Foresight News, Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company, has announced plans to strategically expand into the cryptocurrency and blockchain sectors. The company intends to establish a subsidiary named 'American BNB Strategy' to lead its digital asset investment and management initiatives.
Through this platform, Liminatus aims to raise and deploy up to $500 million in phases, focusing on strategic long-term investments in BNB. The company views this expansion into digital assets as a necessary step to support long-term growth and enhance shareholder value.
Liminatus Pharma is dedicated to developing immunotherapies for cancer patients and is advancing a range of novel therapies targeting cancer antigens and tumor-specific immune responses.
